1 August 2012
Ensuring Drug Quality in Global Health Programs
The report examines the regulatory and policy requirements intended to ensure the quality drugs procured with US aid funds and the systems in place to monitor drug quality in supply chain used by receiving US aid funds. It finds that the US-funded global health programs have put regulatory and policy requirements in place to help prevent procurement of substandard drugs. Reliance on implementing partners however potentially introduces risks related to capacity and corruption.
This is a work of the US government and is not subject to copyright protection in the United States. The published product may be reproduced and distributed in its entirety without further permission from GAO.
David Gootnick, Marcia Crosse
US Government Accountability Office (GAO), Washington, DC
no keywords assigned